Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Voyageur Secures First International Sales Contract worth US$1.9 Million (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mawson Infrastructure Group Inc MIGI

Technology Software - Application
Mawson Infrastructure Group, Inc. is a digital infrastructure company. The Company operates data centers for the generation of Bitcoin cryptocurrency (also known as Bitcoin mining), in the United States. The Company has three primary businesses, including digital currency or Bitcoin self-mining, customer co-location and related services, and energy markets. Bitcoin mining involves the use of... see more

Recent & Breaking News (NDAQ:MIGI)

Wize Pharma and Cosmos Capital enter into Bid Implementation Agreement

PR Newswire December 30, 2020

Wize Pharma Announces Positive Topline Results in Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome

PR Newswire November 12, 2020

Wize Pharma's Strategic Transaction Partner Bonus BioGroup to Present MesenCure Data at the International Society for Cell & Gene Therapy (ISCT) Annual Meeting on May 28-29, 2020

PR Newswire May 27, 2020

Wize Pharma's Strategic Transaction Partner Bonus BioGroup Reports Successful Treatment of Acute Pneumonia in Preclinical COVID-19 Model

PR Newswire May 18, 2020

Wize Pharma Completes Phase IV Study of LO2A for the Treatment of Dry Eye Syndrome in Patients with Sjögren's Syndrome

PR Newswire May 7, 2020

Wize Pharma's Strategic Transaction Partner Bonus Biogroup Initiates Preclinical Study for Treatment of Respiratory Distress in COVID-19 Patients

PR Newswire April 21, 2020

Wize Pharma Completes Bonus BioGroup Strategic Transaction

PR Newswire February 20, 2020

Wize Pharma Completes Patient Enrollment In Phase IV Study Of LO2A for the Treatment of Dry Eye Syndrome in Patients With Sjögren's Syndrome

PR Newswire January 21, 2020

Wize Pharma Executes Agreements for Strategic Transaction With Bonus BioGroup

PR Newswire January 16, 2020

Wize Pharma Lenders Convert $760,000 of Loans Into Equity

PR Newswire December 3, 2019

Wize Pharma Enters Exclusive License Agreement for Ophthalmic Non-viral Gene Therapy Technology

PR Newswire September 9, 2019

Wize Pharma Retains Life Science Advisory Firm Lighthouse BioPartners to Support Potential Pharma Partnership Deals for its Lead Asset LO2A

PR Newswire July 8, 2019

Wize Pharma Completes Milestone for Joint Venture With Cannabics Pharmaceuticals; Companies to Develop Cannabinoid Ophthalmic Treatments

PR Newswire June 28, 2019

Wize Pharma Interview to Air on Bloomberg International on the RedChip Money Report June 16, 2019

PR Newswire June 14, 2019

Wize Pharma to Present at ThinkEquity Conference on May 2, 2019 in New York City

PR Newswire April 30, 2019

Wize Pharma Announces Positive Results in First Controlled Study of Treatment for Dry Eye Syndrome in Patients With Conjunctivochalasis

PR Newswire April 29, 2019

Wize Pharma's CEO Noam Danenberg Increases Stake in Company

PR Newswire April 24, 2019

Wize Pharma Appoints Mark Sieczkarek as Chairman of the Board, Noam Danenberg to Become Chief Executive Officer

PR Newswire April 23, 2019

LO2A Licensor, Resdevco, Granted Market Approval for the Treatment of Sjögren's Syndrome in Hungary

PR Newswire March 11, 2019

Cannabics Pharmaceuticals Closes Agreement With Wize Pharma

PR Newswire March 6, 2019